CALR and essential thrombocythemia: Several studies have shown that JAK2V617F-mutated ET patients had older age, lower platelet counts, higher hemoglobin levels, higher leukocyte counts, and higher thrombotic risk compared with CALR-mutated cases (Al Assaf et al., 2015; Cazzola and Kralovics, 2014; Tefferi et al., 2014).